IL6 and lung carcinoma: In A549 (lung cancer), instead, while the benefit of IL6 was not high enough to prevent the KO clone from growing, the cost was low enough that the cost/benefit ratio was high enough to drive the spread of the KO clone, but the result was a coexistence of the two clones without a substantial reduction in average cell growth.